Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $115000.0.

  • Zentalis Pharmaceuticals' Cash from Financing Activities rose 2500.0% to $115000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $304000.0, marking a year-over-year increase of 18148.15%. This contributed to the annual value of $108000.0 for FY2024, which is 9995.45% down from last year.
  • Zentalis Pharmaceuticals' Cash from Financing Activities amounted to $115000.0 in Q3 2025, which was up 2500.0% from $189000.0 recorded in Q1 2025.
  • Zentalis Pharmaceuticals' 5-year Cash from Financing Activities high stood at $236.6 million for Q2 2023, and its period low was $7000.0 during Q1 2024.
  • Its 4-year average for Cash from Financing Activities is $41.6 million, with a median of $341000.0 in 2023.
  • Per our database at Business Quant, Zentalis Pharmaceuticals' Cash from Financing Activities crashed by 9999.62% in 2024 and then skyrocketed by 260000.0% in 2025.
  • Quarter analysis of 4 years shows Zentalis Pharmaceuticals' Cash from Financing Activities stood at $49.7 million in 2022, then plummeted by 99.38% to $309000.0 in 2023, then tumbled by 70.23% to $92000.0 in 2024, then rose by 25.0% to $115000.0 in 2025.
  • Its Cash from Financing Activities stands at $115000.0 for Q3 2025, versus $189000.0 for Q1 2025 and $92000.0 for Q3 2024.